Syndicated Research Report Diagnostics

Hepatitis E Diagnostic Tests Market

Size, Share & Industry Analysis, By Test Type (ELISA and automated serology, Rapid antibody tests, Molecular HEV RNA tests, Other HEV-specific assays), By Application (Acute hepatitis diagnosis, Chronic and transplant monitoring, Outbreak and surveillance testing, Other clinical indications), By End User (Hospitals, Reference laboratories, Public-health laboratories, Other clinical facilities), By Sample Type (Serum and plasma, Whole blood, Stool and other specimens), and Global Forecast, 2026-2034

Report ID 24LS-9474
Pages 97
Last Updated
Author 24LifeSciences Research Team
Industry Diagnostics
Starting from $995 USD

Market Overview

2026 Market SizeUSD 41.7 MnBase year
2027 EstimateUSD 42.6 MnEstimated year
2036 ForecastUSD 51.0 MnForecast value
CAGR2.0%2027–2036
Largest RegionAsia-Pacific2026

Hepatitis E Diagnostic Tests Market Overview

The global hepatitis E diagnostic tests market is valued at USD 41.7 million in 2026 and estimated at USD 42.6 million in 2027. Revenue is projected to reach USD 51.0 million by 2036, representing a 2.0% CAGR during 2027–2036.

20 millionEstimated annual HEV infections worldwideWHO, July 2026
3.3 millionEstimated symptomatic infections annuallyWHO, July 2026
4,431Estimated HEV deaths in 2023WHO, July 2026
IgMPrimary serological marker of recent infectionWHO and Mayo Clinic Laboratories

Hepatitis E diagnostic testing includes HEV-specific IgM and IgG antibody assays, rapid immunochromatographic tests and HEV RNA detection or quantification. These assays help distinguish hepatitis E from clinically similar viral hepatitis and support outbreak investigations, transplant care and assessment of acute jaundice. General liver-function testing, hepatitis A–D testing and hepatitis E vaccine sales fall outside the market boundary.

The World Health Organization estimated 20 million HEV infections annually, including 3.3 million symptomatic infections, in its July 2026 fact sheet. Transmission through contaminated water creates substantial testing needs in parts of South and East Asia and sub-Saharan Africa, while zoonotic exposure creates sporadic cases in higher-income countries. Diagnostic demand depends on recognition of unexplained hepatitis, testing access and laboratory capacity rather than on infection incidence alone.

WHO identifies anti-HEV IgM detection as a usual basis for confirming infection, with reverse-transcription PCR particularly useful in uncommon or chronic cases. Mayo Clinic Laboratories offers both reflex-confirmed IgM serology and quantitative RNA testing. Fortress Diagnostics and MP Biomedicals market rapid HEV IgM tests, while Dia.Pro and Mikrogen offer laboratory immunoassays. Fortress lists a serum/plasma rapid HEV IgM cassette, while Mayo offers reference-laboratory HEV RNA quantification.

In immunocompromised patients, HEV antibodies may appear late or be difficult to interpret, increasing the clinical value of molecular detection. Mayo Clinic Laboratories describes serum HEV RNA quantification for diagnosis and monitoring of chronic infection. Procurement decisions therefore depend on assay performance, clinical indication, reagent availability and whether a product is authorized for diagnostic use in the purchasing jurisdiction.

Source: WHO hepatitis E; CDC hepatitis E; Mayo HEV RNA; Fortress HEV rapid.

Key Takeaways: Hepatitis E Diagnostic Tests Market

  • Base-year size: The market is valued at USD 41.7 million in 2026 across HEV-specific diagnostic assays and associated testing.
  • Forecast: Revenue is estimated at USD 42.6 million in 2027 and forecast at USD 51.0 million by 2036, a 2.0% CAGR.
  • Leading test type: HEV antibody immunoassays represented an estimated ~67% of 2026 revenue, reflecting routine IgM screening and IgG testing.
  • Leading application: Acute hepatitis diagnosis represented an estimated ~58% of 2026 revenue, led by evaluation of unexplained jaundice.
  • Largest region: Asia-Pacific represented an estimated ~39% of 2026 revenue, reflecting endemic transmission and laboratory demand.
  • Clinical demand: WHO estimates 20 million infections annually and identifies HEV IgM as a standard diagnostic marker.
  • Competition: Dia.Pro, Fortress Diagnostics, Mikrogen, MP Biomedicals and bioM - rieux supply differentiated serological or rapid-testing formats.
  • Coverage: The study forecasts 2027–2036 revenue across four segmentation axes and five geographic regions.

Report Scope & Market Segmentation

Revenue includes HEV-specific in-vitro diagnostic tests and associated laboratory assay services, excluding unrelated hepatitis panels, liver chemistry and research-only reagent sales.

Report AttributeCoverage
Base Year2026
Estimated Year2027
Forecast Period2027–2036
Market MeasurementRevenue, USD million/billion
By Test TypeELISA and automated serology; Rapid antibody tests; Molecular HEV RNA tests; Other HEV-specific assays
By ApplicationAcute hepatitis diagnosis; Chronic and transplant monitoring; Outbreak and surveillance testing; Other clinical indications
By End UserHospitals; Reference laboratories; Public-health laboratories; Other clinical facilities
By Sample TypeSerum and plasma; Whole blood; Stool and other specimens
By RegionNorth America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Selected CountriesUnited States; Canada; Germany; France; China; India; Japan; Brazil; South Africa
Key Market PlayersDia.Pro Diagnostic Bioprobes; Fortress Diagnostics; MP Biomedicals; Mikrogen; bioM - rieux; altona Diagnostics; Mayo Clinic Laboratories

Market Definition & Revenue Boundaries

Included revenue derives from HEV-specific IgM and IgG ELISA and automated immunoassays, HEV rapid antibody cassettes, molecular assays cleared or otherwise permitted for clinical use, and the HEV-attributable component of laboratory test services. Generic PCR instruments and broad hepatitis diagnostic panels are counted only to the extent of HEV-specific consumables or services.

Products labeled research-use-only are excluded from clinical diagnostic revenue unless separately sold under a valid diagnostic authorization. The four dimensions classify the same underlying market by method, clinical use, purchaser and specimen; their values are not additive across dimensions. Molecular HEV RNA testing is particularly relevant for immunosuppressed and transplant patients.

Hepatitis E Diagnostic Tests Market Dynamics

Drivers Impact Analysis*

Market DriversImpact RankCAGR Contribution (%)2027–20292030–20322033–2036
Outbreak-related demand for HEV IgM screeningHigh+1.10%HighMediumMedium
Molecular monitoring in immunosuppressed patientsMedium+0.80%MediumHighHigh
Expanded automated and rapid test availabilityMedium+0.60%MediumMediumMedium
Greater recognition of zoonotic transmissionLow+0.40%MediumMediumHigh
Others (clinical laboratory menu expansion)Low+0.20%LowMediumMedium

Restraints Impact Analysis*

Market RestraintsImpact RankCAGR Contribution (%)2027–20292030–20322033–2036
Low routine screening penetrationHigh-0.50%HighMediumMedium
Limited laboratory access in outbreak settingsMedium-0.35%HighMediumMedium
Regulatory and reimbursement fragmentationLow-0.15%MediumMediumLow
Others (procurement and training constraints)Low-0.10%MediumLowLow

*CAGR contribution shows the percentage points each factor adds to or removes from the 2.0% CAGR for 2027–2036; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

Waterborne outbreaks create demand for confirmatory assays

WHO reports that hepatitis E spreads mainly through contaminated drinking water in areas with limited sanitation. An outbreak can generate a sudden need for IgM serology and rapid tests because clinical symptoms resemble other causes of acute hepatitis. Laboratories must distinguish suspected cases from other infections before public-health officials can assess transmission and respond. In displacement settings, access to electricity, cold chains and trained staff can determine whether rapid field tests or centralized immunoassays are used. The resulting purchasing pattern is episodic and geographically concentrated rather than a steady global screening program.

Transplant and immunosuppressed patients need molecular testing

Mayo Clinic Laboratories notes that immunosuppressed patients can develop prolonged HEV viremia and that antibody responses may be delayed. Quantitative HEV RNA testing can therefore provide diagnostic and monitoring information when serology alone is insufficient. Specialized laboratories serving transplant centers require validated extraction, amplification and calibration procedures. The need for repeat viral-load measurements supports molecular test utilization even in countries where acute hepatitis E is uncommon. However, testing remains targeted to patients with relevant clinical indications, limiting the overall market relative to broadly screened viral infections.

Serology formats enable different laboratory purchasing models

Dia.Pro supplies HEV IgM ELISA, Mikrogen offers recomWell HEV antibody assays, and bioM - rieux lists VIDAS Anti-HEV IgM and IgG tests. Automated platforms can support routine laboratory throughput, while plate-based methods suit laboratories with existing ELISA infrastructure. Rapid cassette products from Fortress Diagnostics and MP Biomedicals support settings where instrument access is constrained. Procurement choices depend on turnaround requirements, available instruments, specimen handling and local regulatory authorization. Multiple formats create competition in assay cost and convenience without changing the clinical need for confirmatory interpretation.

Low recognition and limited routine screening constrain adoption

The CDC notes that hepatitis E is uncommon in the United States and requires laboratory testing for diagnosis. Symptoms overlap with hepatitis A and other causes of liver injury, so HEV-specific testing may not be ordered unless clinicians consider travel, food exposure or immunosuppression. Unlike routinely screened hepatitis B and C, hepatitis E testing is often indication-driven. Lower clinical awareness and inconsistent access to validated assays can delay recognition of sporadic infections. This limits recurrent testing volume in low-incidence markets even as specialized reference laboratories expand their menus.

Research-use-only products cannot be treated as diagnostic sales

altona Diagnostics lists its RealStar HEV RT-PCR Kit 2.0 as research-use-only and explicitly states it is not for diagnostic procedures. A broad count of every HEV-related molecular product would therefore overstate clinically eligible diagnostic supply. Laboratory purchasers need to verify regulatory status, intended use and local conformity requirements before adopting a test. The market boundary counts clinical HEV-specific tests and services, not research-only reagents or the full revenue of multipurpose PCR instruments. This distinction matters particularly for molecular platforms that serve numerous pathogens beyond HEV.

Sources: WHO; CDC; Mayo Clinic Laboratories; Dia.Pro; Mikrogen; Fortress Diagnostics; MP Biomedicals; altona Diagnostics.

Hepatitis E Diagnostic Tests Market Segmentation by Test Type

Report Segmentation
By Test Type

Hepatitis E diagnostic tests include laboratory antibody immunoassays, rapid serology, molecular RNA tests and specialized HEV assays. WHO identifies IgM serology as the usual diagnostic confirmation method.

Largest Test Type

ELISA and automated serology

ELISA and automated serology represented an estimated ~67% of 2026 revenue. Dia.Pro, Mikrogen and bioM - rieux offer HEV-specific antibody assays for routine laboratories. IgM supports recent-infection assessment while IgG helps evaluate prior exposure, and laboratories may choose automated systems or microplate workflows based on existing instrumentation.

Specialized Molecular Testing

HEV RNA tests

Mayo Clinic Laboratories offers quantitative HEV RNA testing, which is relevant for chronic infection and immunosuppressed patients. RNA assays require validated amplification and laboratory controls; their higher technical complexity concentrates use in specialist settings. altona Diagnostics explicitly labels its RealStar HEV RT-PCR kit as research-use-only and not for diagnostic procedures.

Rapid HEV IgM cassettes from Fortress Diagnostics and MP Biomedicals provide additional options for sites with limited instrumentation. MP Biomedicals states that its CE ASSURE HEV IgM rapid test is sold outside the United States. Laboratory immunoassays also allow batch processing and integration with existing clinical quality-control systems. Interpretation requires attention to the interval between exposure and antibody development, and a negative result early in infection may not exclude HEV. Molecular testing can resolve selected cases but entails additional extraction and instrument resources. For outbreak procurement, laboratories must distinguish professional in-vitro diagnostic products from research-use-only reagents. The relative demand for each format depends on clinical indications, public-health capacity and test access.

Hepatitis E Diagnostic Tests Market Segmentation by Application

Report Segmentation
By Application

Applications span acute hepatitis diagnosis, monitoring of persistent infection, outbreak investigation and other targeted clinical uses. Test selection depends on immune status and the time since exposure.

Largest Application

Acute hepatitis diagnosis

Acute hepatitis diagnosis represented an estimated ~58% of 2026 revenue. WHO notes that hepatitis E cannot be reliably distinguished from other acute viral hepatitis by symptoms alone. HEV-specific IgM assays therefore support evaluation of jaundice and liver injury when epidemiological or clinical findings suggest infection.

Specialist Application

Chronic and transplant monitoring

Mayo Clinic Laboratories documents the utility of HEV RNA testing in immunosuppressed patients, whose antibody responses can be delayed. Transplant centers and specialist laboratories may use repeat molecular tests to assess persistent viremia and treatment response.

Outbreak and surveillance testing responds to contaminated-water events and public-health needs, whereas chronic monitoring creates a smaller but more specialized repeat-testing channel. Pregnant patients with suspected hepatitis E warrant particular clinical attention because WHO identifies a higher risk of severe disease, especially later in pregnancy. A laboratory diagnosis can inform supportive care and outbreak investigation, but the test itself does not determine disease severity. In low-incidence countries, clinicians may consider HEV when other hepatitis markers are negative and there is relevant travel or food exposure. In high-incidence areas, acute case finding can be linked to water-safety investigations and community surveillance.

Hepatitis E Diagnostic Tests Market Segmentation by End User

Report Segmentation
By End User

HEV-specific testing is purchased or delivered through hospitals, reference laboratories, public-health laboratories and smaller clinical facilities. Mayo Clinic Laboratories performs specialized HEV RNA testing, while Fortress offers a rapid HEV IgM cassette.

Hospital Demand

Hospitals

Hospitals evaluate acute liver injury, pregnancy-related complications and transplant patients. Their assay selection depends on clinical urgency and whether molecular testing is performed in-house or referred to a specialist laboratory.

Reference Laboratory Role

Reference laboratories

Mayo Clinic Laboratories lists HEV IgM reflex confirmation and quantitative RNA testing. Reference laboratories support clinicians who do not have routine HEV assays on site, especially in lower-incidence markets.

Public-health laboratories coordinate outbreak-related testing, while smaller facilities may use rapid methods or refer specimens to centralized laboratories. Public-health programs may require flexible procurement during sudden clusters of jaundice rather than maintaining large routine stocks. Hospitals with transplant services need reliable molecular referral arrangements, while regional laboratories can standardize antibody testing through shared instrumentation. In remote settings, availability of electricity, sample transport and trained personnel shapes the feasible diagnostic workflow. Supplier selection also requires attention to the country-specific regulatory status of each test and the practical cost of quality controls. These operational differences affect the mix of rapid devices, ELISA reagents and molecular testing services. Turnaround time can be shortened when hospital and reference laboratory information systems exchange test orders and results without manual re-entry. Mayo Clinic Laboratories recommends correlating HEV RNA findings with clinical presentation and relevant testing history.

Hepatitis E Diagnostic Tests Market Segmentation by Sample Type

Report Segmentation
By Sample Type

Specimen selection depends on the assay method and clinical indication. Serological products primarily use blood-derived specimens, while molecular methods can analyze selected clinical specimens.

Routine Specimens

Serum and plasma

Dia.Pro describes HEV IgM ELISA for human plasma and serum, and Mayo Clinic Laboratories lists serum for its HEV IgM screening and RNA assays. These specimens align with existing clinical chemistry and infectious-disease laboratory workflows.

Alternative Specimens

Whole blood and stool

Some rapid assays accept whole blood, while WHO notes that HEV RNA can be detected in blood and stool. The approved specimen types must be verified from each product label rather than inferred across test technologies.

Laboratory protocols, sample transport and storage requirements influence test choice and result turnaround, particularly during remote outbreaks. Serum and plasma are widely used for HEV antibody assays because existing blood-collection workflows support routine immunology testing. Whole-blood use is assay-specific and should not be generalized from one rapid test to another. Stool molecular testing can provide additional evidence of viral shedding, but sample processing and transport may be more complex than serum testing. For molecular assays, specimen suitability and detection thresholds depend on the validated method. Procurement teams must follow the instructions for use, since sample compatibility affects analytical reliability and whether a result can support a clinical decision. Quality-assurance procedures and traceable controls are essential when laboratories introduce new specimen types.

Hepatitis E Diagnostic Tests Market Regional Analysis

Regional demand reflects the epidemiology of waterborne and zoonotic HEV, access to laboratory testing, clinical recognition and availability of validated IgM and RNA assays. WHO identifies South and East Asia and sub-Saharan Africa as major disease-burden areas.

North America

Specialist testing - Reference-laboratory driven

North American demand is concentrated in reference laboratories, hospitals and transplant centers rather than broad routine population screening. CDC describes hepatitis E as uncommon in the United States, with many cases historically linked to travel and some linked to animal-derived foods. Physicians evaluating unexplained acute hepatitis may order HEV IgM tests, while immunocompromised patients can require HEV RNA quantification. Mayo Clinic Laboratories offers both serological screening with reflex confirmation and quantitative RNA testing. This menu structure supports access without requiring every community laboratory to run HEV assays locally. U.S. demand is therefore sensitive to clinical awareness, transplant activity and laboratory referral practices. Canada faces related questions of zoonotic transmission, specimen referral and specialist access. The market includes the HEV-specific portion of laboratory services and test reagents, not all general hepatitis diagnostic activity.

Priority country signals

United States

Selected market signal

CDC states that hepatitis E requires laboratory diagnosis and is uncommon domestically. Mayo Clinic Laboratories offers an HEV IgM antibody screen with reflex confirmation and quantitative RNA testing. Mayo lists an IgM reflex screen and a separate quantitative HEV RNA assay for patients requiring molecular assessment. In the United States, specialist reference laboratories provide molecular options for immunocompromised patients. This supports referral testing rather than universal HEV screening.

Source: CDC.

Canada

Selected market signal

Canadian laboratory demand is shaped by assessment of unexplained hepatitis and specialized referral pathways. Molecular testing may be useful when antibody responses are unreliable in immunosuppressed patients, as described by Mayo Clinic Laboratories. In Canada, clinicians may consider zoonotic exposure and travel history when requesting HEV testing. Mayo offers HEV RNA testing as a reference-laboratory service for patients with suspected persistent infection.

Source: Mayo Clinic Laboratories.

Europe

Laboratory capacity - Serology and RNA workflows

European HEV testing spans routine hospital immunology, reference-laboratory molecular diagnostics and public-health surveillance. HEV genotype 3 can be transmitted zoonotically, so clinicians may investigate infections without travel to endemic areas. Mikrogen markets recomWell HEV IgG and IgM immunoassays and recomLine confirmatory formats, providing examples of specialized serology supply. Dia.Pro also offers HEV-specific antibody tests, while bioM - rieux lists VIDAS Anti-HEV IgM and IgG assays for automated laboratory workflows. Regulatory conformity and clinical intended use remain important to purchasing decisions. Specialized molecular testing serves transplant and other immunosuppressed populations, but research-use-only reagents must be separated from clinical diagnostic sales. Laboratories in Germany, France and neighboring markets may use centralized workflows to achieve quality control and consistent interpretation. Regional value depends on clinical testing indications, assay pricing and laboratory utilization rather than population size alone. Testing strategies also differ according to the availability of specialist clinicians and the use of centralized public-health reference facilities. HEV-specific serology is not interchangeable with routine liver enzyme testing.

Priority country signals

Germany

Selected market signal

Mikrogen offers recomWell HEV IgG and IgM assays as well as recomLine HEV tests. These products illustrate the role of specialist immunodiagnostics suppliers in European laboratories. German suppliers include Mikrogen, whose recomWell and recomLine portfolios address HEV antibody detection and confirmation. Mikrogen identifies its recomWell HEV products as in-vitro diagnostic assays for human serum or plasma.

Source: Mikrogen.

France

Selected market signal

bioM - rieux lists VIDAS Anti-HEV IgM and IgG tests within its hepatitis assay portfolio. Automated immunoassay workflows can help laboratories incorporate HEV testing into existing infrastructure. French laboratory automation includes bioM - rieux VIDAS anti-HEV assays. The available platform and sample throughput influence whether hospitals conduct testing internally. bioM - rieux lists VIDAS Anti-HEV IgM and IgG tests with defined kit sizes and turnaround times.

Source: bioM - rieux.

Asia-Pacific

Largest region - ~39% of 2026 revenue

Asia-Pacific represented an estimated ~39% of 2026 revenue in the publisher-normalized model. WHO identifies East and South Asia among regions with substantial hepatitis E burden, reflecting both waterborne transmission and differences in sanitation and public-health infrastructure. Clinical laboratories use HEV-specific IgM tests to investigate acute hepatitis, while molecular methods support selected complicated or chronic cases. Demand varies sharply between large tertiary hospitals, regional laboratories and remote outbreak settings. Rapid tests may be operationally attractive when instrument access is limited, although local authorization and performance requirements still apply. China and India represent different procurement environments, with urban laboratory networks operating alongside areas where sample transport is difficult. Japan also faces zoonotic exposure pathways and specialist diagnostic needs. The forecast assumes modest revenue growth rather than proportional growth with infection incidence, because many infections are asymptomatic and access to confirmatory testing is uneven.

Priority country signals

China

Selected market signal

WHO identifies HEV genotypes with distinct human and zoonotic transmission routes and notes the availability of an HEV vaccine in China. HEV-specific testing remains necessary for clinical diagnosis and outbreak investigation. In China, HEV prevention includes a licensed vaccine, while diagnostic assays remain relevant for suspected cases. WHO describes human transmission for HEV genotypes 1 and 2 and zoonotic transmission for genotypes 3 and 4.

Source: WHO.

India

Selected market signal

Waterborne transmission and acute jaundice investigations create demand for HEV IgM testing. Rapid assays and ELISA workflows serve different infrastructure settings, with diagnostic access depending on laboratory capacity and procurement. In India, contaminated-water outbreaks can create concentrated diagnostic needs. Rapid testing and centralized ELISA may serve different clinical settings depending on local resources.

Source: WHO.

Latin America

Targeted demand - Outbreak and referral testing

Latin American HEV testing is concentrated in laboratories investigating unexplained acute hepatitis and in specialized services supporting immunosuppressed patients. The infection can be difficult to distinguish clinically from other viral causes of jaundice, making HEV-specific antibody detection important when exposure history or local epidemiology warrants testing. WHO describes both waterborne and zoonotic transmission pathways, which create differing surveillance needs across countries. Urban hospitals and national reference laboratories may operate immunoassay and molecular workflows, while smaller facilities rely on sample referral or rapid formats. Procurement is sensitive to funding, reagent availability, quality controls and training. Brazil and Mexico have different health-system structures, so a single regional adoption assumption would obscure country-level variation. The revenue model counts HEV-specific assays and services, not broad liver-function or other viral hepatitis testing. Growth remains dependent on diagnostic recognition and access rather than systematic population screening. In countries with limited access to molecular platforms, antibody assays and specimen referral may play a larger role. WHO reports that waterborne HEV outbreaks can affect hundreds to thousands of people in exposed communities.

Priority country signals

Brazil

Selected market signal

HEV-specific antibody assays can support the evaluation of acute hepatitis when other causes are excluded. WHO identifies anti-HEV IgM as a common confirmatory test, with RT-PCR detecting viral RNA in selected cases. In Japan, zoonotic HEV exposure is a consideration in unexplained hepatitis. WHO identifies HEV IgM antibody testing and RT-PCR as complementary diagnostic methods. WHO reports that nearly half of HEV outbreaks occur in displacement camp settings.

Source: WHO.

Mexico

Selected market signal

HEV has been reported in epidemiological discussions of Latin America, and targeted laboratory testing may be appropriate for unexplained hepatitis. Dia.Pro describes HEV IgM ELISA for serum and plasma, whereas Fortress lists a rapid HEV IgM cassette. In Brazil, testing of suspected cases depends on laboratory access and clinical recognition. HEV-specific assays are distinct from general liver-function tests. WHO describes HEV-specific IgM detection as the usual diagnostic confirmation method.

Source: Mayo Clinic Laboratories.

Middle East & Africa

Outbreak sensitivity - Water and sanitation exposure

Middle East and Africa testing demand is shaped by waterborne outbreaks, displacement settings and unequal laboratory infrastructure. WHO identifies sub-Saharan Africa as a high-burden area and notes that nearly half of outbreaks occur in camp settings such as refugee or internally displaced person camps. Outbreak response may require rapid access to HEV IgM screening, specimen referral and centralized confirmatory testing. Clinical demand is particularly important for pregnant patients because WHO describes increased risk of severe disease later in pregnancy. Laboratories face practical constraints involving electricity, transport, trained staff and reagent supply. Hospitals in major cities can perform ELISA or molecular workflows, while remote health facilities may depend on rapid devices where authorized and appropriate. The market remains modest in revenue terms despite substantial disease burden, because purchasing capacity and diagnostic access vary widely. Expanded surveillance could improve case recognition but should not be equated directly with commercial test sales.

Priority country signals

South Africa

Selected market signal

Laboratory and public-health systems may investigate HEV in patients with unexplained hepatitis or relevant exposures. Testing requires HEV-specific assays because clinical presentation overlaps other causes of liver injury. In Mexico, travel and exposure histories can inform requests for HEV antibody testing. Mayo Clinic Laboratories notes that HEV RNA testing is important for immunosuppressed patients with delayed antibody responses. WHO identifies anti-HEV IgM and viral RNA detection as methods for confirming HEV infection.

Source: WHO.

Regional humanitarian settings

Selected market signal

WHO identifies displacement camps as important outbreak settings. Rapid diagnostic access and safe sample referral are relevant where centralized laboratory infrastructure is limited. In South Africa, regional diagnostic access differs between large laboratories and remote facilities. Mayo Clinic Laboratories specifies serum specimens for its HEV RNA quantification assay. Mayo Clinic Laboratories offers HEV IgM screening with reflex confirmation for serum specimens.

Source: WHO.

Competitive Landscape

Competition in hepatitis E diagnostic testing spans immunoassay manufacturers, rapid-test suppliers, molecular assay developers and reference laboratories. Supplier portfolios differ by intended use, specimen type, automation and geographic regulatory status.

ELISA Specialists

Dia.Pro and Mikrogen

Dia.Pro markets an HEV IgM ELISA for human serum and plasma, while Mikrogen offers recomWell HEV IgG and IgM tests and recomLine confirmation formats. These products serve laboratory serology workflows and emphasize HEV-specific antibody detection.

Rapid Testing

Fortress Diagnostics and MP Biomedicals

Fortress Diagnostics lists an HEV IgM rapid cassette and HEV ELISA products. MP Biomedicals markets the ASSURE HEV IgM Rapid Test for sale outside the United States. MP Biomedicals labels its CE ASSURE HEV IgM test for sale outside the United States.

Automated Testing

bioM - rieux

bioM - rieux lists VIDAS Anti-HEV IgM and IgG assays in its hepatitis portfolio. Automated immunoassays can support standardized processing in laboratories that already operate compatible instrumentation.

Molecular and Services

Mayo Clinic Laboratories and altona Diagnostics

Mayo Clinic Laboratories provides quantitative HEV RNA testing for clinical use. altona Diagnostics lists an HEV RT-PCR research-use-only kit, which demonstrates molecular technology availability but is excluded from clinical diagnostic sales without appropriate authorization.

The market is fragmented across specialist manufacturers rather than dominated by a single broad viral hepatitis platform. Product differentiation involves antigen selection, clinical sensitivity, sample compatibility, laboratory throughput and regulatory labeling. Supplier claims must be assessed for each HEV-specific product instead of inferred from general hepatitis testing portfolios. The use of HEV-specific assays can differ between acute cases, epidemiological studies and follow-up of persistent infection. The same supplier may offer several formats, but clinical and research-use-only products must be distinguished. Competition also reflects access to distributor networks and training for clinical laboratories.

Reference laboratory access remains important where hospital laboratories do not routinely perform HEV testing. Mayo Clinic Laboratories provides IgM screening with reflex confirmation and molecular quantification, illustrating complementary service pathways. Commercial revenue from laboratory services must be attributed only to the HEV-specific component to avoid counting unrelated laboratory procedures. WHO reports that HEV RNA can be detected in blood and stool using RT-PCR, and Mayo Clinic Laboratories describes RNA monitoring for transplant recipients. These methods complement HEV-specific IgM assays, which WHO identifies as the usual confirmatory diagnostic approach.

Key Companies Profiled

  • Dia.Pro Diagnostic Bioprobes
  • Fortress Diagnostics
  • MP Biomedicals
  • Mikrogen
  • bioM - rieux
  • altona Diagnostics
  • Mayo Clinic Laboratories

Recent Developments in the Hepatitis E Diagnostic Tests Market

July 2026: WHO updated its hepatitis E fact sheet, estimating 20 million annual infections and describing anti-HEV IgM testing and RT-PCR as diagnostic approaches. The update highlights the continuing relevance of serological and molecular testing. WHO also distinguishes genotypes associated with waterborne outbreaks from those associated with zoonotic transmission, making clinical context important when selecting diagnostic methods. Source

November 2026: CDC published its hepatitis E basics page, emphasizing that laboratory testing is necessary for diagnosis and describing risks for pregnant and immunocompromised people. The guidance supports targeted clinical recognition rather than universal screening. The CDC page notes that infection can follow contaminated water or undercooked animal products and that most patients recover without specific treatment. Source

May 2024: CDC published viral hepatitis laboratory-testing resources linking to hepatitis E diagnostic information. CDC includes HEV within its laboratory-testing information for viral hepatitis. Laboratories use these resources alongside assay-specific instructions to interpret test results and select appropriate confirmation pathways for patients with suspected infection. CDC lists HEV within viral hepatitis laboratory testing resources. Source

May 2024: CDC published its viral hepatitis serology training series, including a dedicated hepatitis E module. CDC includes a dedicated hepatitis E module in its viral hepatitis serology training series. Training supports recognition of serological markers and helps clinicians distinguish HEV-specific findings from those of other viral hepatitis infections. CDC provides a dedicated hepatitis E serology training module. Source

Current portfolio: Mikrogen lists recomWell HEV IgG and IgM assays and recomLine HEV IgG/IgM tests, demonstrating continued availability of specialized antibody testing formats. The product pages do not establish a new launch date. Product documentation describes separate IgG and IgM testing and cross-reactivity with HEV genotypes, relevant to laboratory assay selection and interpretation. Source

Current portfolio: Fortress Diagnostics lists both an HEV IgM rapid test cassette and HEV ELISA kits. These are current product listings rather than independently dated product launches. Their portfolio illustrates the availability of rapid and conventional laboratory formats, although actual adoption depends on local diagnostic authorization and purchasing conditions. Source

Market Outlook, 2027–2036

The hepatitis E diagnostic tests market is projected to rise from USD 42.6 million in 2027 to USD 51.0 million in 2036, reflecting a 2.0% CAGR during 2027–2036. Growth remains tied to targeted clinical testing and outbreak surveillance.

Forecast VariableStarting PointExpected Effect Through 2036
Clinical recognitionHEV resembles other acute hepatitisGradual expansion of targeted IgM testing
Molecular testingSpecialist use for immunosuppressed patientsAdditional RNA monitoring demand
Outbreak responseWaterborne outbreaks in endemic regionsEpisodic rapid and ELISA procurement
AutomationExisting serology platformsSteady adoption in equipped laboratories
Regulatory statusCountry-specific assay intended useLimits substitution of RUO products
AccessUneven laboratory infrastructureConstrains realized demand in high-burden settings

Clinical awareness of HEV in patients with unexplained acute hepatitis should support selective testing, particularly where exposure history suggests contaminated water or animal-derived food. WHO identifies IgM serology as a common confirmation method, so laboratory immunoassays are expected to remain central to test utilization. WHO estimates that 3.3 million people develop symptomatic HEV infection annually, but not every symptomatic case reaches a laboratory. This limits conversion of epidemiological burden into commercial diagnostic revenue.

Molecular HEV RNA testing will retain a specialist role in immunosuppressed and transplant patients. Mayo Clinic Laboratories describes the use of quantitative RT-PCR for persistent viremia and monitoring. Growth in this application depends on clinical protocols and reference-laboratory capacity rather than universal population screening. Immunosuppressed patients may have delayed antibody responses, so molecular detection addresses a distinct clinical need from standard IgM testing. Mayo Clinic Laboratories describes an HEV RNA quantification assay with a stated detection limit and specified serum specimens.

Asia-Pacific remains the largest modeled regional market, while sub-Saharan Africa has substantial infection burden but more limited diagnostic purchasing capacity. The forecast separates disease incidence from commercial test revenue and does not assume that all symptomatic infections result in a paid laboratory test. WHO also identifies displacement camps as important outbreak settings, where test access may be constrained by transport and laboratory infrastructure. Fortress Diagnostics lists a rapid HEV IgM cassette, whereas Mayo Clinic Laboratories provides centralized RNA quantification.

The principal uncertainties are assay access, reimbursement, outbreak frequency, regulatory authorization and the availability of trained laboratory personnel. Suppliers with validated HEV-specific serology, rapid devices and molecular services can address different needs, but research-only reagents are not included in clinical sales.

Report Coverage

The report evaluates HEV-specific diagnostic revenue, clinical demand and product competition using the 2026 base year and forecasts through 2036.

Market Sizing2026 market size, 2027 estimate, 2036 forecast and CAGR for 2027–2036.
Test TypeLaboratory serology, rapid HEV antibody assays, molecular RNA testing and other HEV-specific tests.
Clinical ApplicationsAcute hepatitis diagnosis, chronic infection monitoring, outbreak testing and other indications.
End Users and SpecimensHospital, reference and public-health laboratories; serum, plasma, blood and other validated specimens.
Regional AnalysisNorth America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Competitive LandscapeHEV-specific suppliers, clinical intended-use distinctions and specialized laboratory services.

Frequently Asked Questions

How large is the hepatitis E diagnostic tests market?

The market is valued at USD 41.7 million in 2026, estimated at USD 42.6 million in 2027 and projected to reach USD 51.0 million by 2036. This model counts HEV-specific clinical diagnostic products and testing services while excluding unrelated liver chemistry and research-only reagents.

What is the forecast growth rate?

The publisher-normalized market model indicates a 2.0% CAGR during the nine-year 2027–2036 period. WHO describes hepatitis E testing as clinically targeted to suspected infection, while CDC states that laboratory testing is necessary for diagnosis. Clinical testing demand depends on HEV-specific diagnostic access.

Which hepatitis E test is used for acute infection?

WHO identifies HEV-specific IgM antibody detection as the usual basis for confirming hepatitis E infection, with clinical context guiding interpretation. Dia.Pro and Mikrogen offer HEV IgM ELISA formats. An assay result must be interpreted with the patient’s symptoms, timing of exposure and clinical context.

When is HEV RNA testing important?

RT-PCR is useful for selected uncommon and chronic infections, especially in immunosuppressed patients with potentially delayed antibody responses. Mayo Clinic Laboratories provides quantitative HEV RNA testing for immunocompromised patients. RNA detection is also useful when HEV antibody responses are delayed.

Which region leads the market?

Asia-Pacific represented an estimated ~39% of 2026 revenue in the modeled geographic allocation. WHO identifies substantial HEV burden in South and East Asia. Modeled revenue share is not equivalent to the regional share of global infections.

What is the leading test type?

ELISA and automated serology represented an estimated ~67% of 2026 revenue, reflecting the role of antibody testing. Dia.Pro and Mikrogen market antibody immunoassays, while bioM - rieux lists automated VIDAS anti-HEV assays. Fortress Diagnostics markets a serum/plasma HEV IgM lateral-flow cassette for professional in-vitro diagnostic use.

Which application is largest?

Acute hepatitis diagnosis represented an estimated ~58% of 2026 revenue, led by testing for suspected recent infection. Acute HEV infection resembles other viral hepatitis syndromes. Laboratory confirmation may be particularly relevant during outbreaks or after suspected exposure.

What causes hepatitis E?

HEV infection can follow contaminated water or zoonotic food exposures. WHO describes distinct transmission patterns across viral genotypes. WHO identifies waterborne transmission for genotypes 1 and 2 and predominantly zoonotic pathways for genotypes 3 and 4.

Which companies provide HEV assays?

Dia.Pro, Mikrogen, Fortress Diagnostics, MP Biomedicals and bioM - rieux have HEV-specific antibody assay offerings. Fortress Diagnostics and MP Biomedicals also supply HEV rapid tests. Product labeling and local regulatory status should be checked before procurement.

Are all HEV PCR kits clinical diagnostic products?

No. Some products, including the altona RealStar HEV RT-PCR research-use kit, are explicitly not intended for diagnostic procedures. altona Diagnostics explicitly labels its RealStar HEV RT-PCR kit as research-use-only. altona Diagnostics specifies that its HEV RT-PCR research-use-only kit is not intended for diagnostic procedures.

Why does hepatitis E require laboratory testing?

The clinical symptoms overlap other causes of acute viral hepatitis, so HEV-specific antibodies or RNA are needed for confirmation. WHO states that anti-HEV IgM is usually used for confirmation. Molecular detection of viral RNA may be necessary for selected patients.

Which patients need specialized follow-up?

Immunosuppressed patients, including organ transplant recipients, may need HEV RNA testing when persistent infection is suspected. Mayo Clinic Laboratories describes chronic HEV in immunocompromised patients and the value of RNA monitoring. Mayo Clinic Laboratories describes the clinical use of HEV RNA monitoring in immunocompromised transplant recipients.

Research Sources & Evidence Base

View research sources used for this overview
  1. WHO. Hepatitis E fact sheet, July 2026.
  2. CDC. Hepatitis E Basics, November 2026.
  3. Dia.Pro. HEV IgM ELISA.
  4. Mayo Clinic Laboratories. HEV IgM antibody screen.
  5. Mayo Clinic Laboratories. HEV RNA quantification.
  6. Fortress Diagnostics. HEV IgM rapid test.
  7. Fortress Diagnostics. HEV ELISA portfolio.
  8. altona Diagnostics. RealStar HEV RT-PCR RUO, July 2017.
  9. CDC. Viral hepatitis laboratory testing, May 2024.
  10. CDC. Viral hepatitis serology training, May 2024.
  11. Dia.Pro. HEV product portfolio.
  12. MP Biomedicals. ASSURE HEV IgM rapid test.
  13. Mikrogen. recomWell HEV.
  14. Mikrogen. recomLine HEV.
  15. bioM - rieux. VIDAS hepatitis panel.
Trusted collaboration

Supporting teams across the life-sciences ecosystem

Focused market intelligence for commercial, strategy, product, and research teams across healthcare and life sciences.

Bain
Deloitte
PwC
Commercial Healthcare Partners
Client logo
Client logo
Life-sciences market focus Clear scope and sample review Confidential enquiry support

Display logos only where use is approved. A logo does not imply a public endorsement.

Client feedback

What teams value in their research experience

Feedback from research engagements, with client identities omitted where confidentiality applies.

Publish named testimonials only when the individual and organization have approved disclosure.

Research transparency

Built on a clearly defined research framework

Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.

Defined Market Scope

Coverage, segmentation, geography, and market boundaries are stated within the report.

Evidence-Led Overview

Readers can review the published sources and evidence referenced in this market overview.

Forecast Context

Base, estimated, and forecast years are shown to place the market outlook in context.

Current Publication Record

Each overview displays its report identifier and latest update date.

Report ID 24LS-9474
Base Year 2026
Forecast Period 2026–2036
Last Updated 16 Nov 2026
Inside the full report

What you can explore in this market report

A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.

01

Market Sizing & Forecasts

Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.

02

Segmentation Analysis

Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.

03

Regional Market View

Assess regional performance, selected country context, and factors shaping adoption across major markets.

04

Competition & Developments

Explore company profiles, market positioning, and selected developments relevant to the market landscape.

05

Market Dynamics & Trends

Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.

06

Research Methodology & Sources

Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.